Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

Year end trading update

19 Jan 2009 07:00

RNS Number : 8037L
Cello Group plc
19 January 2009
 



19 January 2009

  

Cello Group plc

Year end trading update

 

Cello Group plc ("Cello" or the "Group", AIM: CLL), the leading independent market research and consulting group, today provides the following trading update for the year ended 31 December 2008

 

Since the announcement of the Group's interim results in early September, trading has tightened across certain sectors of Cello's broad domestic and international client base As a result, the Board anticipates that the Group's results for the full year will be at the lower end of market expectations.

There has been very strong cash conversion in the second half of 2008, as a result of which the Board expects to report year end net debt of less than £10.5m, significantly below consensus expectations.

The Group has agreed enlarged banking facilities with the revolving credit facility now increased from £18.0m to £20.0m for 2009, amortising to £17.0m for 2010. The overdraft facility of £2.0m has also been renewed and is now a multi-currency arrangement. The extra interest cost associated with these changes is expected to be broadly offset by lower overall interest rates.

The Group has re-estimated its total anticipated earn out obligations. These are now expected to be £15.2m compared with a previous estimate of £19.2m, with a minimum loan note component of £6.3m and the balance of £8.9m payable in shares. £7.8m of this total is anticipated to be settled in May 2009 with £3.2m payable in loan notes and £4.6m payable in shares. The balance of the total earn out commitment is payable between 2010 and 2013, with a loan note payment of £0.6m expected to be paid in 2010. The Group is entitled to pay an increased proportion of these total obligations in loan notes.

As well as the strong operating cash position and the reduced earn out provisions, the Group has continued to prudently reduce its cost base. In total over £2.0m of staff costs, on an annualised basis, have been removed during 2008.

Allan Rich, whose appointment as Acting Non-Executive Chairman was announced on September 2008has been confirmed as Non-Executive Chairman. Allan brings with him a wealth of experience of managing successfully through economic downturns.

 

The Group remains realistically cautious about the current outlook. While it is too early to give detailed guidance, numerous clients have indicated their intention to maintain their expenditure levels and the Group is seeing refreshed levels of spend from several of its public sector clients. In addition, all of Cello's investment start-up businesses are now trading profitably. All these factors, including the Group's strong financial position, should hold the Group in good stead in the current economic environment.

 

Cello expects to announce its preliminary results for the year ended 31 December 2008 on Tuesday 17 March 2009.

 

Enquiries

 

Cello Group 

 

Mark ScottChief Executive

020 7812 8460

Mark Bentley, Finance Director

 

Singer Capital Markets

 

Nicholas How

020 3205 7620

 

 

College Hill

 

Adrian Duffield/Rozi Morris

020 7457 2020

 

 

Notes to Editors (www.cellogroup.co.uk)

 

Cello is a market research and consulting group that listed on AIM in November 2004.

 

The Group's strategy is to create value for shareholders by building a world class market research business and a leading direct response business.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGUUACGUPBGAQ
Date   Source Headline
29th Jun 20077:01 amRNSDirector/PDMR Shareholding
28th Jun 20077:01 amRNSDirectorate Change
8th Jun 20077:01 amRNSAcquisition
22nd May 20071:00 pmRNSAGM Statement
16th May 20079:43 amRNSShare Option Grants
1st May 20074:15 pmRNSAnnual Report and Accounts
1st May 20074:13 pmRNSShare Option Grants
27th Apr 200712:41 pmRNSDirector/PDMR Shareholding
26th Apr 20077:01 amRNSInvestment
10th Apr 20079:44 amRNSTotal voting rights update
2nd Apr 20073:48 pmRNSDirector/PDMR Shareholding
30th Mar 20077:01 amRNSAcquisition
29th Mar 20072:07 pmRNSHolding(s) in Company
20th Mar 20077:01 amRNSFinal Results
9th Mar 20071:18 pmRNSHolding(s) in Company
28th Feb 20074:53 pmRNSHolding(s) in Company
19th Feb 200711:14 amRNSNotice of Results
2nd Feb 20073:05 pmRNSTotal Voting Rights
29th Jan 20077:01 amRNSAcquisition
19th Jan 20073:19 pmRNSHolding(s) in Company
11th Jan 20077:01 amRNSPre Close Trading Statement
15th Dec 20069:01 amRNSDirector/PDMR Shareholding
12th Dec 20069:00 amRNSTotal Voting Rights
30th Nov 20063:56 pmRNSHolding(s) in Company
13th Nov 200612:48 pmRNSAnalyst/Investor Presentation
5th Oct 20065:10 pmRNSNotifiable Interest
4th Oct 20063:53 pmRNSHolding(s) in Company
26th Sep 20067:03 amRNSAcquisition
11th Sep 20063:58 pmRNSHolding(s) in Company
5th Sep 20067:02 amRNSInvestment in Digital Agency
5th Sep 20067:02 amRNSInterim Results
17th Aug 20069:54 amRNSNotice of Results
26th Jul 20062:17 pmRNSAdditional Listing
3rd Jul 200611:53 amRNSAdditional Listing
3rd Jul 20067:01 amRNSPre Close Trading Statement
3rd Jul 20067:01 amRNSControlling Stake
26th Jun 20063:23 pmRNSInvest in brand consulting op
26th Jun 20067:19 amRNSAcquisition
21st Jun 200612:15 pmRNSAnnual Report and Accounts
19th Jun 20063:22 pmRNSMajor Interest in Shares
23rd May 200612:58 pmRNSAGM Statement
27th Mar 20065:46 pmRNSMajor Interest in Shares
27th Mar 20065:05 pmRNSMajor Interests in Shares
21st Mar 20063:39 pmRNSHolding(s) in Company
16th Mar 20067:00 amRNSPerformance Share Option Plan
15th Mar 20067:01 amRNSDirector/PDMR Shareholding
14th Mar 20067:05 amRNSShare Option Plan
14th Mar 20067:02 amRNSFinal Results
20th Feb 20065:19 pmRNSNotice of Results
25th Jan 20063:11 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.